Nord/LB set a €94.00 ($109.30) price target on Merck KGaA (FRA:MRK) in a report issued on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
Other analysts have also recently issued research reports about the company. DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, April 15th. Barclays set a €82.00 ($95.35) target price on Merck KGaA and gave the stock a sell rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, May 13th. Finally, UBS Group set a €104.00 ($120.93) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, May 13th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the stock. Merck KGaA has a consensus rating of Hold and a consensus target price of €101.35 ($117.85).
MRK opened at €91.02 ($105.84) on Friday. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: Trading Ex-Dividend
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.